⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295325 | 0.82 | PRMT1 (0.46) | — | |
| SCHEMBL23499777 | 0.80 | PRMT1 (0.50) | — | |
| SCHEMBL23499673 | 0.80 | PRMT1 (0.50) | — | |
| SCHEMBL10776715 | 0.80 | ALDH1A1 (0.43) | — | |
| SCHEMBL501649 | 0.77 | — | — | |
| SCHEMBL2511728 | 0.76 | — | — | |
| SCHEMBL23499694 | 0.75 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL27032850 | 0.75 | ECE1 (0.30) | — | |
| SCHEMBL4047411 | 0.75 | CYP2D6 (0.45) | — | |
| SCHEMBL6894584 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024075075-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | RENEXXION IRELAND LIMITED (IE) | 2024-04-11 | — | — | WO | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3976185-B1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2024-02-14 | — | — | EP | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | HURT CLARENCE (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3230282-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | AbbVie Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230283-A1 | BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | AbbVie Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229844-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | AbbVie Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2017100171-A1 | ANTIFUNGAL COMPOUNDS AND METHODS | KALYRA PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094517-A1 | BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094505-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| EP-0213914-A2 | Clavam derivatives, preparation and intermediates therefor | BEECHAM GROUP PLC (GB) | 1987-03-11 | — | — | EP | disclosed |